On its third quarter earnings call last week, Dexcom recapped a busy Q3 — of note, one that included the acquisition of TypeZero Technologies for $11.3 million in August as well as two new FDA clearances in October and November. One of these clearances was for a new mobile app interface for the Dexcom G6 while the other was the Dexcom Pro Q CGM, a new disposable glucose monitoring device intended...
Senseonics and TypeZero's R&D partnership around the artificial pancreas is leveling up. The two organizations announced today that they would team up with pharmaceutical and medical device company Roche to launch three European clinical trials of their combined closed-loop system. The research is backed by the National Institutes of Health (NIH) through its International Diabetes Closed Loop...
Virtual medical assistant company Sensely is collaborating with the Mayo Clinic to ascertain how to leverage patient engagement and chronic disease monitoring technology. The partnership will blend the Mayo Clinic’s triage algorithms and clinical expertise with Sensely’s patient engagement platform in hopes of assessing and predicting which resources can be best used at the right time to help...
A new partnership in the diabetes space could bring the promise of an artificial pancreas closer to reality. Senseonics, a Germantown, Maryland company working on a pill-sized, implantable continuous glucose monitor that can last 90 days without needing replacement, will work with digital, personalized medicine company TypeZero Technologies on a project to integrate readings from Senseonics...
